<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671814</url>
  </required_header>
  <id_info>
    <org_study_id>1986-016</org_study_id>
    <secondary_id>TR701-101</secondary_id>
    <nct_id>NCT00671814</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults</brief_title>
  <acronym>SAD/MAD</acronym>
  <official_title>A Double-Blind, Placebo and Active Controlled, Single and Multiple Rising Dose, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      single rising oral doses and multiple oral doses of TR-701
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an evaluation of TR-701 in a double-blind, placebo-controlled, randomized, single
      (Part A) and multiple (Part B) ascending dose safety, tolerance, and PK when administered as
      a capsule in normal, healthy adult volunteers. The study will be sequential between Part A
      and Part B (i.e., not staggered or leap frogged), with slight overlap between last cohort in
      Part A and first cohort in Part B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2008</start_date>
  <completion_date type="Actual">June 6, 2008</completion_date>
  <primary_completion_date type="Actual">June 6, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event reporting</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The PK rate and extent of urinary excretion of TR-701 and its microbiologically active moiety, TR-700</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral doses of 600mg linezolid given twice daily for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701</intervention_name>
    <description>TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid</intervention_name>
    <description>Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  in good health

          -  body mass index of 20 to 29.9 kg/m2

          -  female subjects must be either postmenopausal for at least 1 year, surgically sterile,
             abstinent, or agree to use an effective method of birth control

        Exclusion Criteria:

          -  history or clinical manifestations of any clinically significant disorder

          -  history of hypersensitivity or allergies to any drug compound

          -  history of stomach or intestinal surgery or resection

          -  history of alcoholism or drug addiction within 1 year

          -  use of any tobacco-containing or nicotine-containing products within 6 months

          -  use of any other medications

          -  use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or
             beverages; or foods or beverages with high levels of tyramine

          -  pregnancy, lactation, or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Bohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibiotic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Torezolid phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

